Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Msd K.k.

Other

Mark E Layton

Michael J Kelly, Iii

Philip E Sanderson

Joseph E Pero

Anthony J Roecker

Jian Liu

James J Perkins

Christopher James Bungard

Kevin J Rodzinak

Michael A Rossi

Deping Wang

Jason M Cox

Christopher S Burgey

Hong Liu

James J Mulhearn

Ting Zhang

Kristen L G Jones

Zhe Wu

Ian M Bell

Jun Liang

Ashok Arasappan

Dansu Li

Shawn J Stachel

Liangqin Guo

Ronald M Kim

Thomas J Greshock

Harry R Chobanian

Jiabing Wang

Michael J Breslin

Vadim Y Dudkin

Walter Won

Linda M Suen-Lai

Alexander J Reif

Yasuhiro Goto

Philippe G Nantermet

Toshihiro Sakamoto

Yoshio Ogino

Rajan Anand

Kenneth L Arrington

Lianyun Zhao

Scott E Wolkenberg

Xuanjia Peng

Zhijian Zhao

Nicholas D P Cosford

Essa H Hu

Jeffrey Curtis Kern

Hidetomo Furuyama

Nobuhiko Kawanishi

Anthony T Ginnetti

Deodial Guy Guiadeen

Gang Zhou

Takashi Mita

Kevin F Gilbert

Yiwei Li

Tianying Jian

Pablo De Leon

Yu Onozaki

Xiu Wang

Hannah D G F Lehman

Hannah D Fiji

Craig William Lindsley

Nigel J Liverton

Mark E Fraley

Mark T Bilodeau

John A McCauley

Melissa S Egbertson

Christopher D Cox

Younong Yu

Brian Andrew Stearns

Steven D Young

Jeannie M Arruda

Wayne J Thompson

Peter J Manley

Lida R Tehrani

Helen Y Chen

Izzat Tiedje Raheem

Tony Siu

John W Butcher

Brian T Campbell

Charles J McIntyre

Timothy John Hartingh

John E Stelmach

Jacob M Hoffman

Peter M Munson

Mehul F Patel

Hiroshi Hirai

Brian T Phillips

Akira Naya

Hidehito Kotani

Jeffrey W Schubert

Michael David VanHeyst

Christine Dieckhaus

Willie Whitter

Donna J Armstrong

Michael J Rossi

Akshay A Shah

Vadim Dudkin

Swati I P Mercer

Disclosed are compounds of Formula A, or a salt thereof: Wherein 'A', R, R, R, R, and Rare as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch and neuropathic pain disorders using the same.

Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 

Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same. 

N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein 'Het', R, and Rare defined herein, which have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating neuropathic pain disorders using the same. 

Benzoxazolinone compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A-a, or a salt thereof: Where 'B' and 'R' through &#x201c;R&#x201d; are as defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same. 

Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula Aand Formula A: wherein 'Heteroaryl-1', R, R, R, and Rare defined herein, which novel compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae Aand Aor their salts, and methods of treating neuropathic pain disorders using the same. 

N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels

The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluRreceptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Imidazopyridin-2-one derivatives

Disclosed are compounds of Formula (A) or a salt thereof, wherein 'Het', R, and Rare defined herein, which have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A) or their salts, and methods of treating neuropathic pain disorders using the same. 

The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Positive allosteric modulators of mGluR2

Growing community of inventors

Harleysville, PA, United States of America

Mark E Layton